Repatha’s withdrawal from Denmark is best understood as an early signal of the impact of Most Favored Nation drug pricing ...

Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...

Amgen’s first quarter results reflected the company’s ability to outpace the impact of ongoing patent expirations and ...

Repatha, a PCSK9 inhibitor, lowers cholesterol well, especially for those intolerant to statins, but its absolute risk ...

I’m a 75-year-old woman who’s in very good health. Since my early 50s, I’ve had issues with my cholesterol. My ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a ...

Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Amgen has announced a price reduction for Repatha (evolocumab), bringing the list price of the therapy to $5,850 per year, ...

Amgen reported long-awaited positive outcomes data for its PCSK9 inhibitor, Repatha, which it believes will help make the case for the drug to payers. The data, released Friday at the American College ...

It’s not known whether Repatha (evolocumab) is safe to use while pregnant or breastfeeding. Certain factors may determine whether you should use the drug during this time. It’s not known whether it’s ...

Amgen stock toppled Friday as investors digested its "generally in-line" first-quarter report and expansion in the obesity treatment space.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

For all the talk about new opportunities for consumers to make their own healthcare decisions, much remains out of their control. Nowhere is that more evident than in the prescription drug market, ...